Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 7, 1998, Pages 531-540

  Gourevitch, M N ^a,c   Alcabes, P ^b   Wasserman, W C ^a   Arno, P S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Drug users; HIV infection; Prevention; Tuberculosis

Indexed keywords

ISONIAZID;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FEMALE; HEPATITIS; HIGH RISK POPULATION; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; TUBERCULOSIS;

ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; ISONIAZID; MALE; NEW YORK; PATIENT COMPLIANCE; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0031851551     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Frieden T R, Fujiwara I P, Washko R M, Hamburg M A. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-233.
2. Chaulk C P, Moore-Rice K, Rizzo R, Chaisson R E. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274: 945-951.
3. Murray C J L, DeJonghe E, Chum H J, Nyangulu D S, Salomao A, Srvblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338: 1305-1308.
4. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treat- ment of tuberculosis: we can't afford not to try it. N Engl J Med 1993; 328: 576-678.
5. Fryatt R J. Review of published cost-effectiveness studies on tuberculosis treatment programmes. Int J Tuberc Lung Dis 1977; 1: 101-109.
6. Moore R D, Chaulk C P, Griffiths R, Cavalcante S, Chaisson R E. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996; 154: 1013-1019.
7. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
8. Rieder H L. Case finding. In: Reichman L B, Hershfield E S (eds). Tuberculosis: a comprehensive international approach. New York: Marcel Dekker 1993: pp. 167-182.
9. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 17: 28-106.
10. Rose D N, Schlechter C B, Fahs M C, Silver A L. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med 1988; 4: 102-109.
11. Snider D E, Caras G J, Koplan J P. Preventive therapy with isomazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579-1583.
12. Adhikari N, Menzies R. Community-based tuberculin screening in Montreal: a cost-outcome description. Am J Public Health 1995; 85: 786-790.
13. Foster S, Godfrey-Faussett P, Porter J. Modeling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997; 11: 919-925.
14. Reichman L B, Felton C P, Edsall J R. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979; 139: 337-339.
15. Markowitz N, Hansen N I, Hopewell P C, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 1997; 126: 123-132.
16. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989; 320: 545-550.
17. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119: 194-198.
18. Selwyn P A, Sckell B M, Alcabes P, Friedland G H, Klein R S, Schoenbaum E E. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268: 504-509.
19. Daley C L, Hahn J A, Hopewell P C, Moss A R, Schecter G F. Incidence of tuberculosis (TB) in injection drug users (IDU) in San Francisco (SF), 1990-94. The Lancet Conference on Tuberculosis, September 14-15, 1995; abstr 11.
20. Gourevitch M N, Wasserman W, Panero M, Arno P. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1996; 15: 93-104.
21. Selwyn P A, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1697-1703.
22. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990; 142: 725-735.
23. Centers for Disease Control. Screening for tuberculosis and tuberculous infection in high-risk populations; and the use of preventive therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1990; 39 (RR-8): 1-12.
24. Stimmel B, Vernace S, Schaffner F. Hepatitis B surface antigen and antibody: a prospective study in asymptomatic drug abusers. JAMA 1975; 234: 1135-1138.
25. Schoenbaum E E, Hartel D, Selwyn P A, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med 1989; 321: 874-879.
26. Daley C L, Small P M, Schecter G F, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231-235.
27. Gordin F M, Matts J P, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 337: 315-320.
28. Arno P S, Murray C J L, Bonuck K A, Alcabes P. The economic impact of tuberculosis in hospitals in New York City: a preliminary analysis. J Law Med Ethics 1993; 21: 317-323.
29. Brown R E, Miller B, Taylor W R, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155: 1595-1600.
30. Gold M R, Siegel J, Russell L B, Weinstein M C, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
31. Pape J W, Jean S S, Ho J L, Hafner A, Johnson W D. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-272.
32. De Cock K M, Grant A, Porter J D H. Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research and practice. Lancet 1995; 345: 833-836.
33. Graham N M H, Galai N, Nelson K E, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996; 156: 889-894.
34. Brewer T F, Heymann S J, Colditz G A, et al. Evaluation of tuberculosis control policies using computer simulation. JAMA 1996; 276: 1898-1903.
35. Centers for Disease Control. Improving patient compliance in tuberculosis treatment programs. 1989: 3-4.
36. Centers for Disease Control and Prevention. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR 1997; 46 (RR-15): 1-10.
37. Fujiwara P I, Cook S V, Rutherford C M, et al. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997; 157: 531-536.
38. Centers for Disease Control. Outbreak of multidrug-resistant tuberculosis - Texas, California, and Pennsylvania. MMWR 1990; 39: 369-372.